Overview
A significant pharmaceutical supply contract for the immunotherapy medication pembrolizumab has been awarded by the Budgetary Institution of the Khanty-Mansi Autonomous District-Yugra "Nizhnevartovsk Oncological Dispensary." On December 2, 2025, the RUB 102.6 million contract was signed, guaranteeing patients in the area continuous access to vital oncology drugs in 2026.
Overview of the Contract
The agreement, which is presently in the execution stage, covers the supply of pembrolizumab for medical use. The contract was completed in compliance with Article 93 of Federal Law No. 44-FZ, which permits procurement from a single supplier, after an electronic auction process that was ruled invalid.Important Contract Information
Value of Contract: RUB 102,608,000.00
Date of Contract: December 02, 2025
Date of Contract Registration: December 3, 2025
Method of Procurement: Electronic auction (finished with a single supplier)
Status of Contract: Execution
Location of the Project: Russian Federation
Treasury/Banking Support: Not necessary
Purchaser Information
Purchaser: Yugra's Khanty-Mansi Autonomous District Budgetary Institution
"Oncological Dispensary in Nizhnevartovsk"Sector: Oncology and public health services
The goal is to obtain cutting-edge immunotherapy drugs for the treatment of cancer by 2026.
Successful Provider
Company: "Implementation Centre 'PROTEK'" Joint Stock Company (JSC CV PROTEK)
Address: 22, Building 4, Kashirskoye Highway, Moscow, Russia
Contact number: +7 495 737 34 00
Email address: protek_tender@protek.ru
One of the top distributors of pharmaceuticals in Russia, JSC CV PROTEK is heavily involved in large-scale public healthcare procurement projects at both federal and regional institutions.
Relevance of the Award
A valuable immunotherapy medication that can save lives, pembrolizumab is used to treat a variety of cancers. This agreement strengthens regional healthcare capacity and treatment continuity by guaranteeing patients in the Khanty-Mansi Autonomous District will always have access to cutting-edge oncological therapies.The award also shows how Russia's public healthcare system is increasingly allocating funds for cutting-edge cancer treatments.
In conclusion
Nizhnevartovsk Oncological Dispensary now has a contract worth RUB 102.6 million that guarantees a steady supply of pembrolizumab through 2026. The agreement emphasises how important structured public procurement is to providing necessary medications and enhancing the quality of cancer care throughout the region.RussiaTenders: Russia's Most Recent Government Contract Awards and Tenders
- RussiaTenders is your reliable resource for the most recent Russian contract awards, RFPs, RFQs, and government tenders
- Visit RussiaTenders to stay informed about the most recent public procurement opportunities and tender notices in Russia
- RussiaTenders has all of the Russian government's contract award notices, eProcurement updates, and tenders
- Use RussiaTenders, the RussiaTenders portal, to investigate current bids, tenders, and procurement opportunities in Russia
- RussiaTenders provides you with contract awards, procurement news, and verified tenders from Russia
#Russia #HealthcareProcurement #Oncology #Pembrolizumab #ContractAward #Pharmaceuticals #PublicTenders #Immunotherapy #GovernmentContracts #CancerTreatment
